VEGFA and neoplasm: In light of the tumor specificity observed here, inhibitors of particular biosynthetic enzymes in the heparin/HS biosynthetic pathway or antibodies to HS may be more effective than the current anti-VEGF antibodies [Avastin® (bevacizumab), Roche].